Company intelligence / Profile preview
Paranta Biosciences
Melbourne, Victoria, Australiaparantabio.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Paranta Biosciences demonstrated promising preclinical efficacy and safety data for PB01, a recombinant human follistatin therapy. The company initiated a Phase I clinical trial in September 2015 for inhaled PB01 in healthy volunteers, with stages evaluating safety, tolerability, and pharmacokinetics. Preclinical studies showed excellent anti-inflammatory and anti-fibrotic properties with an exceptionally benign toxicological profile.
- Therapeutic areas
- OncologyPulmonology
- Modalities
- Recombinant protein
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Hudson Institute of Medical Research (exclusive commercialization rights for cancer program)
Beyond the preview
Go deeper on Paranta Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paranta Biosciences.